David A. Siegel Taysha Gene Therapies, Inc. Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $31,856 - $89,414	-18,100 Reduced 17.11%	87,700 $169,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $75,335 - $206,485	-30,500 Reduced 22.38%	105,800 $394,000
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $533,484 - $1.21 Million	102,200 Added 299.71%	136,300 $889,000
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $389,763 - $654,720	34,100 New	34,100 $397,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $119M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.